Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fingolimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 11/20 | 0.94 |
| ▸ | S1PR3 known ✓ | Q99500 | 9/20 | 0.94 |
| ▸ | S1PR4 known ✓ | O95977 | 7/20 | 0.94 |
| ▸ | S1PR5 known ✓ | Q9H228 | 5/20 | 0.94 |
| ▸ | S1PR2 known ✓ | O95136 | 5/20 | 0.70 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.94 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.94 |
| ▸ | GPR183 | P32249 | 1/20 | 0.94 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.94 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.74 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.74 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394554 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL1372656 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3389578 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3394797 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3390328 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3393539 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3392313 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Fingolimod SCHEMBL7445 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL18904548 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3391728 | 0.97 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-119930716-A | Antigen presenting cell targeted lipids for delivery of nucleic acids, compositions and uses thereof | 上海先博生物科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119523941-A | Bionic antigen presenting cell targeted lipid nanoparticle for delivering nucleic acid and application thereof | 上海先博生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230270696-A1 | MEDICINAL USE OF FINGOLIMOD IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS | CHEN DAN (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-110938003-B | Preparation method of fingolimod hydrochloride | 新发药业有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4035659-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PureTech LYT, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022095610-A1 | MEDICINAL USE OF FINGOLIMOD IN PREVENTING AND TREATING NEURODEGENERATIVE DISEASES CAUSED BY SPHINGOLIPID DISORDERS | 杭州端丽生物技术有限公司 | 2022-05-12 | — | — | WO | disclosed |
| US-20210290538-A1 | MILK VESICLES FOR USE IN DELIVERING BIOLOGICAL AGENTS | PURETECH LYT, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-2720690-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | Children's Medical Center Corporation (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174522-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-12-20 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD (JP) | 2011-01-27 | — | — | US | disclosed |
| US-7825109-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101407471-A | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| CN-1874991-A | Compounds capable of binding to the S1P receptor and pharmaceutical uses thereof | ONO PHARMACEUTICAL CO (JP) | 2006-12-06 | — | — | CN | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | S1PR1 529/4885S1PR3 938/4885S1PR4 791/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 5/4885 |
| US-11059784-B2 | Oxime ether compounds | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 6/4885 |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR4 5/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | S1PR1 3025/4885S1PR3 2627/4885S1PR4 2743/4885 |
| US-20210290538-A1 | MILK VESICLES FOR USE IN DELIVERING BIOLOGICAL AGENTS | CHMP4B, ANXA4, ANXA6 | S1PR1 4216/4885S1PR3 4107/4885S1PR4 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.